Thomsen-Friedenreich Antigen Antibody [A68-B/A11]
| Code | Size | Price |
|---|
| PSI-33-541-100ug | 100ug | £765.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgM, kappa
Antibody Clonality: Monoclonal
Antibody Clone: A68-B/A11
Regulatory Status: RUO
Target Species:
- Human
- Mouse
- Rat
Applications:
- Immunofluorescence (IF)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
Shipping:
blue ice
Storage:
Aliquot and Store at -20C. Avoid freez-thaw cycles.
Documents
Further Information
Application Note:
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT
Optimal dilution of the Thomsen-Friedenreich Antigen antibody should be determined by the researcher.
Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT
Optimal dilution of the Thomsen-Friedenreich Antigen antibody should be determined by the researcher.
Background:
Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide.
Buffer:
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration:
0.2 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Neuraminidase-treated human red blood cells were used as the immunogen for the Thomsen-Friedenreich Antigen antibody.
Physical State:
Liquid
Purification:
PEG precipitation
Research Area:
Other
Swissprot #:
Not Applicable
User NOte:
Optimal dilutions for each application to be determined by the researcher